BAKER BROS. ADVISORS LP 13D and 13G filings for Aerovate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:21 pm Sale | 2024-09-30 | 13G | Aerovate Therapeutics, Inc. AVTE | BAKER BROS. ADVISORS LP | 17,970 2.200% | -30,045 (-62.57%) | Filing |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | BAKER BROS. ADVISORS LP | 48,015 6.100% | -8,467 (-14.99%) | Filing |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | BAKER BROS. ADVISORS LP | 56,482 8.000% | 4,145 (+7.92%) | Filing |
| 2022-02-14 4:14 pm Purchase | 2021-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | BAKER BROS. ADVISORS LP | 52,337 7.500% | 52,337 (New Position) | Filing |